This letter addresses the concerns raised in a series of reports published as letters to the editor in a recent issue of Leukemia (2007) (vol. 21, issue 7) about the role of P-glycoprotein (Pgp) or ABCB1 (ATP Binding Cassette) and ABCG2 in both in vitro and in vivo resistance to imatinib mesylate (Gleevec or STI-571). Rumpold et al. 1 demonstrated that silencing the expression of Pgp in imatinib-resistant chronic myeloid leukemia (CML) cell lines re-sensitized the cells to both imatinib and doxorubicin. Similarly, Widmer et al. 2 developed an analytical method to determine the imatinib content in cellular extracts and showed that the intracellular concentration of imatinib increased by 4-to 9-fold in K562 cells expressing Pgp. They further concluded that the restoration of the imatinib sensitivity observed in these resistant CML cell lines was due to the marked increase in intracellular levels of imatinib. These reports are consistent with the previously published finding that imatinib is a substrate for Pgp and its active efflux by this transporter results in low intracellular concentrations. 3 However, other studies 4, 5 showed that overexpression of Pgp in K562 cells does not confer resistance to imatinib, nor did the specific elimination of Pgp in the hematopoietic system improve the responses of imatinib in a CML animal model. Zong et al. 5 showed that the leukemia initiating cells were not sensitized to imatinib by loss of Pgp, which indicated that there was a very minimal role for Pgp in resistance to imatinib in an in vivo system. They further proposed that one of the possible reasons for not getting positive indications in Pgp-mediated resistance to imatinib in in vivo conditions was because of the inhibitory effect of imatinib on not only Pgp but also other ABC transporters. These authors further speculated that the inhibitory effect of imatinib on these transporters could be because of the possible competition of imatinib with ATP for the nucleotide-binding domain of the ABC transporters because imatinib shares a structural similarity with ATP and has been shown to bind to the ATP-binding pocket in BCR ABL-kinase. 6 We provide biochemical evidence that imatinib interacts with the two major ABC drug transporters Pgp and ABCG2 at the transport-substrate site(s). We studied the effect of imatinib on the photolabeling of Pgp and ABCG2 with the ATP analog, [a- . This observation indicates that, in spite of the similar structures and the fact that these inhibitors bind to the ATP-binding sites of the tyrosine kinase, they seem to interact at different site(s) on the ABC transporters. It is well established that transport substrates of Pgp and ABCG2 stimulate the vanadate (Vi)-induced trapping of nucleotide following a single turnover of ATP hydrolysis. 7 Consistent with these studies, we found that 20 mM imatinib stimulated the Vi-induced trapping of 8-azido ADP by both Pgp and ABCG2 (Figure 1b ). Another useful assay to monitor the interaction of substrates with these transporters is to monitor their effect on the rate of ATP hydrolysis, as the ATP hydrolysis is coupled to the efflux function. We observed that imatinib-stimulated ATP hydrolysis by both Pgp and ABCG2 (Figure 1c ). The concentration required to stimulate 50% of the maximum ATP hydrolysis by imatinib was 0.46 and 0.12 mM for Pgp and ABCG2, respectively. These data are consistent with imatinib-induced stimulation of the nucleotide trapping in the presence of Vi (Figure 1b) .
To verify the interaction of imatinib at the transport substratebinding sites of Pgp and ABCG2, we monitored the effect of imatinib on the crosslinking of 125 I-Iodoarylazidoprazosin (IAAP), a photoaffinity analog of prazosin, which is also a substrate for both Pgp and ABCG2. 8 This is a valuable tool to study the interaction of the agents at the drug substrate-binding pocket of these transporters. Imatinib effectively inhibited the binding of 125 I-IAAP to both Pgp and ABCG2 with IC 50 values of 3.18 and 0.47 mM, respectively (Figure 2 ). It should be noted that we used 10-to 50-fold higher concentrations of imatinib than that required for stimulation of ATP hydrolysis (Figure 1c) or inhibition of IAAP binding (Figure 2 ), for the inhibition for 8-azido ATP-binding and these concentrations had no effect on the incorporation of [a-32 P]-8-azido-ATP, demonstrating that imatinib does not compete for the ATP-binding pocket in these transporters. On the basis of IAAP binding and the ATP hydrolysis data, it is clear that imatinib interacts with these transporters at low micromolar concentrations, which further suggests that imatinib has a relatively high affinity for both these transporters. This is consistent with the observations of OzvegyLaczka et al. 9 and Houghton et al. 10 who, based on in vitro assays, showed that there is a high-affinity interaction of imatinib and other kinase inhibitors with both Pgp and ABCG2. This is also in concordance with our work which showed that imatinib and nilotinib (a new generation TKI) are substrates of the ABCG2 transporter. 11 Transport studies using 14 C-imatinib by at least one of these ABC transporters, ABCG2, are also contradictory. While Houghton et al. 10 showed that 14 Cimatinib was not transported by the ABCG2-expressing Saos2 osteosarcoma cell lines, Burger et al. 12 found that the accumulation of the same was significantly lower in ABCG2-expressing cell lines than in their parental counterparts. On the basis of our data and the work of Ozvegy-Laczka 9 and Houghton et al., 10 it can be postulated that there may be a P]-ATP (2.5 mCi/nmol) in the dark at 371C for 5 min. The reaction was stopped by diluting the samples to 1 ml with cold ATPase assay buffer. The membranes were pelleted by centrifugation at 13 000 r.p.m. for 15 min and were re-suspended in 100 ml of ATPase assay buffer. The samples were then crosslinked by UV illumination on ice, electrophoresed, and analyzed as described above. The autoradiogram from a representative experiment of three independent experiments is shown and the arrows show the positions of Pgp and ABCG2. (c) Imatinib stimulates ATP hydrolysis by both Pgp and ABCG2: crude membranes (100 mg protein/ml) were incubated at 371C with varying concentrations of imatinib in the presence and absence of beryllium fluoride (BeFx; 0.2 mM beryllium sulfate and 2.5 mM sodium fluoride) in ATPase assay buffer for 5 min. The reaction was started by the addition of 5 mM ATP and was stopped by the addition of 0.1 ml of 5% SDS solution. The amount of inorganic phosphate released and the BeFx-sensitive ATPase activity of ABCG2 was determined as described previously. 8 The graph represents the ATP hydrolysis (percent of basal activity; y axis) by Pgp (') and ABCG2 (m) as a function of different concentrations of imatinib (x axis) from a representative experiment of three independent experiments. EGTA, ethylene glycol bis(b-aminoethylether)-N,N,N',N'-tetraacetic acid; SDS-PAGE, sodium dodecyl sulfate; polyacrylamide gel electrophoresis; UV, ultraviolet. narrow concentration range in which the ABC transporters can transport the TKIs. However, because of the high affinity of these compounds, at higher concentrations, TKIs inhibit the function of these proteins. Thus the fact that Houghton et al.
10 used 1 mM of 14 C-imatinib while Burger et al. 12 used 200 nM of the labeled imatinib could explain the contraindication in the findings. Secondly, the fact that human organic cation transporter 1 (hOCT1) has also been proposed to be involved in imatinib disposition 13 also adds another dimension for not observing the imatinib resistance under in vivo conditions as the balance between the efflux (mediated by ABC transporters) and influx (mediated by hOCT1) might determine the intracellular levels of the imatinib. 13 Taken together, in this report, we have used the ATP binding and the vanadate trapping assay to show for the first time that imatinib does not interact at the ATP-binding sites of either Pgp or ABCG2 despite their strong affinity for the ATP-binding pocket of the tyrosine kinases and that it behaves like a transport substrate as it stimulates ATP hydrolysis by these transporters. Using IAAP, we also provide direct evidence for the interaction of imatinib at the transport substrate-binding site(s) of both Pgp and ABCG2. This strengthens the argument that this class of the TKIs are the substrates of the ABC-drug transporters. We suggest that this may also result in development of resistance to this class of drugs in chronic-phase CML patients due to the expression of ABC-drug transporters in addition to the mutation(s) in the tyrosine kinases. Figure 1a except that the labeled ABCG2 was immunoprecipitated using 10 mg of BXP-21 antibody as described previously. 8 The incorporation of [ 125 I]-IAAP into the Pgp and ABCG2 band was quantified by using the STORM 860 phosphor imager system (Molecular Dynamics, Sunnyvale, CA, USA) and the ImageQuaNT software, as described previously. 8 The autoradiogram from a representative experiment of three independent experiments is shown and the arrows mark the position of Pgp and ABCG2. The graph represents the amount of [
125 I]-IAAP incorporated (y axis) as a function of different concentrations of imatinib (x axis) in Pgp (') and ABCG2 (m), respectively.
